arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Neuraxis, INC

NRXS
$7.43 ▲ +0.01 (+0.13%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuraxis, INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $90.1M
Dividend Yield
Revenue Growth 115.7%
Op. Margin -110.2%
ROIC -24.9%
FCF / Share $-0.08
Trailing P/E
Price / Book 13.8x
FCF Yield
Debt / Equity 0.01
info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.93M
↑ +115.7%
Net Income Profit after all expenses
$-1.76M
↑ +22.7%
Operating Margin Operating profit as % of sales
-110.2%
↓ -1.8% 0th
FCF / Share Free cash flow per share
$-0.08
↑ +24.4%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
1
Financial Health
51
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 5 years · 19 quarters